Use of boron-containing polynucleotides as diagnostic agents

• US 5,876,938 A
• Filed: 04/11/1997
• Issued: 03/02/1999
• Est. Priority Date: 08/05/1996
• Status: Expired due to Fees

• Current Assignee: Cambrex Bio Science Rockland, Inc. (Lonza Group AG)
• Original Assignee: Prolinx, Inc.
• Inventors: Stolowitz, Mark L., Kaiser, Robert J.
• Primary Examiner(s): Marschel, Ardin H.
• Assistant Examiner(s): Riley, Jezia
• Application Number:
  US08/837,340
• Time in Patent Office: 690 Days
• Field of Search: 435/6, 536/22.1, 536/23.1, 536/25.32
• US Class Current: 435/6.12
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C07H 23/00 Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12 esters with inorganic acids C07H11/00; metal salts, see parent compounds
• CPC Class Codes: C12P 19/34 Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

Modified nucleotides and polynucleotides which are useful in hybridization assays for the detection of target genes are provided. The modified polynucleotides contain at least one boronic acid moiety which is attached to a nucleotide base in a position which does not interfere with the hydrogen bonding capabilities of that base during duplex formation. The modified polynucleotides are typically formed from naturally occurring nucleotides and one or more modified nucleotides.

Claims

1. A method of detecting the presence of a target nucleic acid in a sample, comprising;

(a) contacting said sample with a modified polynucleotide which is substantially complementary to said target nucleic acid, said modified polynucleotide having the formula;

##STR23## wherein z is an integer of from 1 to 1000;

each R¹¹ is independently selected from the group consisting of --H and --OH;

R¹² and R¹³ are each members independently selected from the group consisting of hydroxyl, protected hydroxyl, monophosphate ester, diphosphate ester and triphosphate ester;

each P¹ and P² is independently selected from the group consisting of --P(O)(OH)--, --P(O)(NH₂)--, --P(S)(OH)--, --P(O)(CH₃)--, and pharmaceutically acceptable salts thereof;

each Nu¹¹, Nu¹² and Nu¹³ is independently selected from the group consisting of ##STR24## adenine, guanine, thymine and cytosine, wherein

X is a linking group comprising of from 3 to 30 carbon atoms;

Y is a boron-containing moiety which forms a complex with detectable boronic acid complexing agents; and

p is an integer of from 1 to 3;

with the proviso that at least one and no more than thirty of Nu¹¹, Nu¹² and Nu¹³ are other than adenine, guanine, thymine or cytosine,

under conditions sufficient to hybridize said modified polynucleotide to said

target nucleic acid thereby forming a hybridized complex;

(b) contacting said hybridized complex with a boronic acid complexing agent, said agent comprising an indicator; and

(c) detecting the presence of said indicator, thereby detecting the presence of said target nucleic acid.

2. A method in accordance with claim 1, wherein said indicator is a fluorescent indicator, electron dense, or an enzyme which produces a detectable substance.

3. A method in accordance with claim 2, wherein said indicator is an enzyme and said detectable substance is detected using calorimetric or chemiluminescent techniques.

4. A method in accordance with claim 2, wherein said indicator is an electron dense indicator selected from the group consisting of ferritin, hemocyanin and colloidal gold.

5. A method in accordance with claim 1, wherein said indicator is a latex sphere or liposome containing a plurality of fluorescent compounds.

6. A method in accordance with claim 1, wherein said boronic acid complexing agent further comprises a moiety selected from the group consisting of salicyl hydroxamic acid and dihydroxybenzohydroxamic acid.

7. A method in accordance with claim 1, wherein said boronic acid complexing agent further comprises a moiety selected from the group consisting of alkyl 1,3-diols and substituted ortho-hydroxy benzohydroxamic acids.